Etelcalcetide Hydrochloride
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Etelcalcetide Hydrochloride |
| DrugBank ID | DB12865 |
| Brand Names (EU) | Parsabiv |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.42% |
Approved Indication (EMA)
Parsabiv is indicated for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on haemodialysis therapy.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | hyperphosphatemia (disease) | 99.42% | DL |
| 2 | esophageal varices with bleeding | 99.35% | DL |
| 3 | esophageal varices without bleeding | 99.35% | DL |
| 4 | varicose disease | 99.09% | DL |
| 5 | glaucoma | 98.92% | DL |
| 6 | pancreatitis | 98.85% | DL |
| 7 | primary hyperoxaluria | 98.74% | DL |
| 8 | primary immunodeficiency syndrome due to p14 deficiency | 98.61% | DL |
| 9 | severe congenital neutropenia | 97.92% | DL |
| 10 | Barth syndrome | 97.84% | DL |
| 11 | familial apolipoprotein C-II deficiency | 97.64% | DL |
| 12 | autosomal recessive severe congenital neutropenia due to JAGN1 deficiency | 97.46% | DL |
| 13 | cyclic hematopoiesis | 97.44% | DL |
| 14 | Steel syndrome | 97.40% | DL |
| 15 | familial hyperphosphatemic tumoral calcinosis/hyperphosphatemic hyperostosis syndrome | 97.40% | DL |
| 16 | tumoral calcinosis, hyperphosphatemic, familial | 97.31% | DL |
| 17 | autosomal recessive severe congenital neutropenia due to G6PC3 deficiency | 97.11% | DL |
| 18 | autosomal recessive severe congenital neutropenia due to CSF3R deficiency | 97.05% | DL |
| 19 | autosomal recessive severe congenital neutropenia due to CXCR2 deficiency | 96.93% | DL |
| 20 | X-linked severe congenital neutropenia | 96.80% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.